07-15-2010: Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCCS) technology platform to screen for small molecule inhibitors of a set of target proteins.

FCCS is a spectroscopic method to measure the interactions of molecules in solution, based on the sensitive detection of single molecules. The proprietary technology of Intana Bioscience allows FCCS to be performed in cellular lysates, thereby characterizing the interactions between small molecules and their target proteins in approximately physiological conditions. In the course of this collaboration, Intana will develop assays and establish a medium to high throughput screening platform for drug discovery projects at Janssen Pharmaceutica N.V. Additionally the technology will provide access to the binding kinetics of identified inhibitors, in support of lead optimization.

Contact / Request information

Request further information free of charge:

Facts, background information, dossiers
More about High-Tech Gründerfonds Management
More about Janssen Pharmaceutica
More about Intana Bioscience
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE